A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study

American Journal of Hematology

Volumn 90, Issue 9, 2015, Pages 811-818

  Hunault Berger, Mathilde ^a   Leguay, Thibaut ^b   Huguet, Françoise ^c   Leprêtre, Stéphane ^d   Deconinck, Eric ^e   Ojeda Uribe, Mario ^f   Bonmati, Caroline ^g   Escoffre Barbe, Martine ^h   Bories, Pierre ⁱ   Himberlin, Chantal ^j   Chevallier, Patrice ^k   Rousselot, Philippe ^l   Reman, Oumedaly ^m   Boulland, Marie Laure ^h   Lissandre, Severine ⁿ   Turlure, Pascal ^o   Bouscary, Didier ^p   Sanhes, Laurence ^q   Legrand, Ollivier ^p   Lafage Pochitaloff, Marina ^r   Béné, Marie C ^k   Liens, David ^s   Godfrin, Yann ^s   Ifrah, Norbert ^a   Dombret, Hervé ^p   more..

^a Haematology Department   (France)

^b Haematology Department of Bordeaux   (France)

^c Haematology Department of Toulouse   (France)

^d Haematology Department of Rouen   (France)

^e Haematology Department of Besançon   (France)

^f Haematology Department of Mulhouse   (France)

^g Haematology Department   (France)

^h Haematology Department of Rennes   (France)

ⁱ Haematology Department of Strasbourg   (France)

^j Haematology Department   (France)

^k Haematology Department of Nantes   (France)

^l Haematology Department of Versailles   (France)

^m Haematology Department of Caen   (France)

ⁿ Haematology Department   (France)

^o Haematology Department of Limoges   (France)

^p ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^q Haematology Department of Perpignan   (France)

^r ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^s ERYTECH PHARMA   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; TRIACYLGLYCEROL LIPASE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ASPARAGINE; DRUG CARRIER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; GERIATRIC PATIENT; GRAM NEGATIVE SEPSIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; INFECTION; MALE; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; SYSTEMIC MYCOSIS; TUMOR LYSIS SYNDROME; AGED; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; CYTOLOGY; DRUG FORMULATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; METABOLISM; MIDDLE AGED; MORTALITY; MYCOSES; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION; SURVIVAL;

AGED; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; ASPARAGINE; DRUG CARRIERS; DRUG COMPOUNDING; ERYTHROCYTES; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOSES; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 84939549863     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24093     Document Type: Article

References (52)

1. Annino L, Goekbuget N, Delannoy A. Acute lymphoblastic leukemia in the elderly. Hematol J 2002;3:219-223.
2. Sancho JM, Ribera, JM, Xicoy B, et al. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol 2007;78:102-110.
3. Sive JI, Buck, G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol 2012;157:463-471.
4. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 2009;113:1408-1411.
5. O'Brien S, Thomas, DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 2008;113:2097-2101.
6. Gokbuget N. How I treat older patients with ALL. Blood 2013;122:1366-1375.
7. Hunault-Berger M, Leguay, T, Thomas X, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica 2011;96:245-252.
8. Sallan SE, Hitchcock-Bryan, S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43:5601-5607.
9. Silverman LB, Gelber, RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-1218.
10. Pession A, Valsecchi, MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:7161-7167.
11. Seibel NL, Steinherz, PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008;111:2548-2555.
12. Moghrabi A, Levy, DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109:896-904.
13. Nagura E, Kimura, K, Yamada K, et al. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1994;33:359-365.
14. Wetzler M, Sanford, BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007;109:4164-4167.
15. Douer D, Aldoss, I, Lunning MA, et al. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol 2014;32:905-911.
16. DeAngelo DJ, Stevenson, KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 2015;29:526-534.
17. Goekbuget N, baumann, A, Beck J, et al. Peg-Asparaginase in adult lymphoblastic leukemia: efficacy and feasability analysis with increasing dose levels. Blood 2008;112:abstract 494.
18. Hamidi M, Zarrin, A, Foroozesh M, et al. Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release 2007;118:145-160.
19. Kwon YM, Chung, HS, Moon C, et al. L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Release 2009;139:182-189.
20. Millan CG, Marinero, ML, Castaneda AZ, et al. Drug, enzyme and peptide delivery using erythrocytes as carriers. J Control Release 2004;95:27-49.
21. He H, Ye J, Wang Y, et al. Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J Control Release 2014;176:123-132.
22. Domenech C, Thomas, X, Chabaud S, et al. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol 2011;153:58-65.
23. Kravtzoff R, Colombat, PH, Desbois I, et al. Tolerance evaluation of L-asparaginase loaded in red blood cells. Eur J Clin Pharmacol 1996;51:221-225.
24. Kravtzoff R, Desbois, I, Lamagnere JP, et al. Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells. Eur J Clin Pharmacol 1996;49:465-470.
25. Goekbuget N, Leguay, T, Hunault M, et al. First European Chemotherapy Schedule for Elderly Patients with Acute Lymphoblastic Leukemia: Promising Remission Rate and Feasible Moderate Dose Intensity Consolidation. Blood 2008;112:304.
26. Godfrin Y, Horand, F, Franco R, et al. International seminar on the red blood cells as vehicles for drugs. Expert Opin Biol Ther 2011;12:127-133.
27. Godfrin Y, Bax B. Enzyme bioreactors as drugs. Drugs Future 2012;37:263-272.
28. O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. Br J Cancer 2006;94:609-613.
29. van der Velden VH, Cazzaniga, G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604-611.
30. Boos J, Werber, G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-1550.
31. Orsonneau JL, Brassart, EA, Lecame M, et al. [Automated kinetic assay of plasmatic L-asparaginase activity undergoing therapy for acute lymphoblastic leukemia]. Ann Biol Clin (Paris) 2004;62:568-572.
32. Wang B, Hak, LJ, Relling MV, et al. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods 2000;239:75-83.
33. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004;60:684-693.
34. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
35. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972;135:185-206.
36. Ribera JM, Garcia, O, Fernandez-Abellan P, et al. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols. Br J Haematol 2012;159:485-488.
37. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003;362:1828-1838.
38. Hunault-Berger M, Chevallier, P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008;93:1488-1494.
39. Caruso V, Iacoviello, L, Di Castelnuovo A, et al. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 2007;5:621-623.
40. De Stefano V, Sora, F, Rossi E, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005;3:1985-1992.
41. Panosyan EH, Seibel, NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26:217-226.
42. Avramis VI, Sencer, S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99:1986-1994.
43. Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr Blood Cancer 2012;59:436-439.
44. Abshire TC, Pollock, BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 2000;96:1709-1715.
45. Jarrar M, Gaynon, PS, Periclou AP, et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer 2006;47:141-146.
46. Tong WH, Pieters, R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 2014;123:2026-2033.
47. Lanvers-Kaminsky C, Westhoff, PS, D'Incalci M, et al. Immediate cooling does not prevent the ex vivo hydrolysis of L-asparagine by asparaginase. Ther Drug Monit 2014;36:549-552.
48. Schwartz PH-BM, Chevallier P, Dreyfus F, et al. French results with the EWALL chemotherapy backbone in older patients with Philadelphia chromosome negative acute lymphoblastic leukemia. A GRAALL report. Haematologica 2013;
49. Pullarkat V, Slovak, ML, Kopecky KJ, et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood 2008;111:2563-2572.
50. Beldjord K, Chevret, S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 2014;123:3739-3749.
51. Martell MP, Atenafu, EG, Minden MD, et al. Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. Br J Haematol 2013;163:458-464.
52. Daenen S, van der Holt, B, Dekker AW, et al. Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a Phase II study for efficacy and feasibility by HOVON. Leukemia 2012;26:1726-1729.